Cancer Cell ‘Hubs’ Targeted with Molecular Switch

In a city, coworking hubs bring people and ideas together. Inside cancer cells, similar hubs form-but instead of fueling progress, they supercharge disease. That’s what researchers at the Texas A&M University Health Science Center (Texas A&M Health) have discovered inside the cells of a rare and aggressive kidney cancer.

Their new study, published in Nature Communications, shows how RNA-normally just a messenger-gets hijacked to build liquid-like “droplet hubs” in the nucleus. These hubs act as command centers, switching on growth-promoting genes. But the team didn’t stop at observing this-they created a molecular switch to dissolve the hubs on demand, cutting off the cancer’s growth at its source.

RNA as a Construction worker

The cancer they’re investigating, called translocation renal cell carcinoma (tRCC), affects children and young adults and currently has almost no effective therapies. It is caused by TFE3 oncofusions-hybrid genes formed when chromosomes swap and fuse in the wrong places.

Until now, how these fusion proteins drove such aggressive tumors remained unclear. The Texas A&M team found that these fusions enlist RNA as structural scaffolds. unlike their traditional role as passive messengers,these RNAs now actively assemble droplets,known as condensates,that cluster key molecules together. These droplets become transcriptional hubs-hotspots that switch on cancer-promoting genes.

“RNA itself is not just a passive messenger,but an active player that helps build these condensates,” said Yun Huang,PhD,professor at the Texas A&M Health Institute of Biosciences and Technology and senior author.

The researchers also discovered that an RNA-binding protein called PSPC1 acts as a stabilizer, reinforcing the droplets and making them even more powerful engines for tumor growth.

How They Cracked the Code

To untangle this hidden process, the team leaned on some of today’s most advanced tools in molecular biology:

• CRISPR gene editing to “tag” fusion proteins in patient-derived cancer cells, letting them track exactly were these proteins go.
• SLAM-seq, a next-generation sequencing method that measures newly made RNA, showing which genes are switched on or off as the droplets form.